Combination immunotherapies for type 1 diabetes mellitus

Nature Reviews Endocrinology

Volumn 11, Issue 5, 2015, Pages 289-297

  Pozzilli, Paolo ^a   Maddaloni, Ernesto ^a   Buzzetti, Raffaella ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CD3 ANTIBODY; DACLIZUMAB; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; IMMUNOMODULATING AGENT; INCRETIN; INTERLEUKIN 2; PROTON PUMP INHIBITOR; RAPAMYCIN; ANTIDIABETIC AGENT;

BODY MASS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CELL LOSS; CELL REGENERATION; CELL TRANSDIFFERENTIATION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; METABOLIC REGULATION; MONOTHERAPY; NATURAL KILLER T CELL; NONHUMAN; ONSET AGE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 1; DRUG COMBINATION; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOTHERAPY; INSULIN-SECRETING CELLS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84929943190     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.8     Document Type: Review

References (108)

1. Levetan, C., Pozzilli, P., Jovanovic, L. & Schatz, D. Proposal for generating new cells in a muted immune environment for type 1 diabetes. Diabetes Metab. Res. Rev. 29, 604-606 (2013).
2. Baekkeskov, S. et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347, 151-156 (1990).
3. Mannering, S. I. et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J. Exp. Med. 202, 1191-1197 (2005).
4. Stadinski, B. D. et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat. Immunol. 11, 225-231 (2010).
5. Strollo, R. et al. HLA-dependent autoantibodies against post-translationally modified collagen type II in type 1 diabetes mellitus. Diabetologia 56, 563-572 (2013).
6. Van Lummel, M. et al. Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes 63, 237-247 (2014).
7. Rondas, D. et al. Citrullinated glucose-regulated protein 78 is an autoantigen in type 1 diabetes. Diabetes 64, 573-586 (2015).
8. Pescovitz, M. D. et al. Rituximab, B-lymphocyte depletion, and preservation of-cell function. N. Engl. J. Med. 361, 2143-2152 (2009).
9. Orban, T. et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378, 412-419 (2011).
10. Harrison, L. C. et al. Pancreatic-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 27, 2348-2355 (2004).
11. Walter, M., Philotheou, A., Bonnici, F., Ziegler, A.-G. & Jimenez, R. No effect of the altered peptide ligand NBI-6024 on-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 32, 2036-2040 (2009).
12. Ludvigsson, J. et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N. Engl. J. Med. 366, 433-442 (2012).
13. Suarez-Pinzon, W. L., Lakey, J. R. T. & Rabinovitch, A. Combination therapy with glucagon-like peptide-1 and gastrin induces-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant. 17, 631-640 (2008).
14. Griffin, K. J., Thompson, P. A., Gottschalk, M., Kyllo, J. H. & Rabinovitch, A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2, 710-718 (2014).
15. Ferrannini, E. The stunned cell: a brief history. Cell Metab. 11, 349-352 (2010).
16. Lebastchi, J. & Herold, K. C. Immunologic and metabolic biomarkers of-cell destruction in the diagnosis of type 1 diabetes. Cold Spring Harb. Perspect. Med. 2, a007708 (2012).
17. Atkinson, M. A., Eisenbarth, G. S. & Michels, A. W. Type 1 diabetes. Lancet 383, 69-82 (2014).
18. Chianelli, M. et al. Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy. Diabetes Metab. Res. Rev. 24, 115-122 (2008).
19. Ueberberg, S. et al. Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic-or-cells in vivo. Diabetes 58, 2324-2334 (2009).
20. Goland, R. et al. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J. Nucl. Med. 50, 382-9 (2009).
21. Robertson, R. P. Estimation of-cell mass by metabolic tests: necessary, but how sufficient Diabetes 56, 2420-2424 (2007).
22. Cernea, S. et al. Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab. Res. Rev. 25, 694-704 (2009).
23. Block, M. B., Rosenfield, R. L., Mako, M. E., Steiner, D. F. & Rubenstein, A. H. Sequential changes in-cell function in insulin-treated diabetic patients assessed by C-peptide immunoreactivity. N. Engl. J. Med. 288, 1144-1148 (1973).
24. Palmer, J. P. et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve-cell function. ADA workshop report. Diabetes 53, 250-264 (2004).
25. Greenbaum, C. J. et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31, 1966-1971 (2008).
26. Pozzilli, P. et al. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal. Diabetes Care 37, 1384-1391 (2014).
27. Kaas, A. et al. Proinsulin, GLP-1, and glucagon are associated with partial remission in children and adolescents with newly diagnosed type 1 diabetes. Pediatr. Diabetes 13, 51-58 (2012).
28. [No authors listed] Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J. Clin. Endocrinol. Metab. 65, 30-36 (1987).
29. [No authors listed] Effect of intensive therapy on residual-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann. Intern. Med. 128, 517-523 (1998).
30. Sosenko, J. M. et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 31, 2188-2192 (2008).
31. Pozzilli, P. et al. Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population-based study. IMDIAB Study Group. Immunotherapy Diabetes. Metabolism 47, 1205-1210 (1998).
32. Pozzilli, P. et al. Is the process of-cell destruction in type 1 diabetes at time of diagnosis more extensive in females than in males Eur. J. Endocrinol. 145, 757-761 (2001).
33. Dabelea, D. et al. Clinical evolution of-cell function in youth with diabetes: the SEARCH for Diabetes in Youth study. Diabetologia 55, 3359-3368 (2012).
34. Greenbaum, C. J. et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 61, 2066-2073 (2012).
35. Barker, A. et al. Age-dependent decline of-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes. Obes. Metab. 16, 262-267 (2014).
36. Törn, C. et al. Prognostic factors for the course of-cell function in autoimmune diabetes. J. Clin. Endocrinol. Metab. 85, 4619-4623 (2000).
37. Picardi, A. et al. Metabolic factors affecting residual-cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes. Horm. Metab. Res. 38, 668-672 (2006).
38. Weets, I. et al. Sex-and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes. Diabetologia 49, 1158-1162 (2006).
39. Petrone, A. et al. Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes Metab. Res. Rev. 21, 271-275 (2005).
40. Pozzilli, P. Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy. Nat. Rev. Endocrinol. 8, 78-80 (2012).
41. Buzzetti, R. et al. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. Diabetes 60, 3067-3072 (2011).
42. Dor, Y., Brown, J., Martinez, O. I. & Melton, D. A. Adult pancreatic-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429, 41-46 (2004).
43. Meier, J. J., Bhushan, A., Butler, A. E., Rizza, R. A. & Butler, P. C. Sustained cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration Diabetologia 48, 2221-2228 (2005).
44. Akerblom, H. K. et al. The case for elimination of cow's milk in early infancy in the prevention of type 1 diabetes: the Finnish experience. Diabetes Metab. Rev. 9, 269-278 (1993).
45. Roep, B. O. et al. Molecular mimicry in type 1 diabetes: immune cross-reactivity between islet autoantigen and human cytomegalovirus but not Coxsackie virus. Ann. NY Acad. Sci. 958, 163-165 (2002).
46. Afonso, G. & Mallone, R. Infectious triggers in type 1 diabetes: is there a case for epitope mimicry Diabetes. Obes. Metab. 15 (Suppl. 3), 82-88 (2013).
47. Brugman, S. et al. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes Diabetologia 49, 2105-2108 (2006).
48. Fousteri, G., von Herrath, M. & Bresson, D. Mucosal exposure to antigen: cause or cure of type 1 diabetes Curr. Diab. Rep. 7, 91-98 (2007).
49. Richardson, S. J., Morgan, N. G. & Foulis, A. K. Pancreatic pathology in type 1 diabetes mellitus. Endocr. Pathol. 25, 80-92 (2014).
50. Chen, Z., Herman, A. E., Matos, M., Mathis, D. & Benoist, C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J. Exp. Med. 202, 1387-1397 (2005).
51. Moran, A. et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381, 1905-1915 (2013).
52. Peakman, M. & von Herrath, M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 59, 2087-2093 (2010).
53. Herold, K. C. et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 56, 391-400 (2013).
54. Herold, K. C. et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62, 3766-3774 (2013).
55. Aronson, R. et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 37, 2746-2754 (2014).
56. Gitelman, S. E. et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 1, 306-316 (2013).
57. Rigby, M. R. et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 1, 284-294 (2013).
58. Sherry, N. A. et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of cells. Endocrinology 148, 5136-5144 (2007).
59. Ablamunits, V. et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 61, 145-154 (2012).
60. Perl, S. et al. Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice. PLoS ONE 8, e67189 (2013).
61. Matthews, J. B., Staeva, T. P., Bernstein, P. L., Peakman, M. & von Herrath, M. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin. Exp. Immunol. 160, 176-184 (2010).
62. Long, S. A. et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs-cell function. Diabetes 61, 2340-2348 (2012).
63. Gottlieb, P. A. et al. Failure to preserve-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 33, 826-832 (2010).
64. Pozzilli, P. & Di Mario, U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 24, 1460-1467 (2001).
65. Mollo, A. et al. Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain. Diabetes. Metab. Res. Rev. 29, 446-451 (2013).
66. Gruessner, R. W. G. & Gruessner, A. C. The current state of pancreas transplantation. Nat. Rev. Endocrinol. 9, 555-562 (2013).
67. Bruni, A., Gala-Lopez, B., Pepper, A. R., Abualhassan, N. S. & Shapiro, A. J. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab. Syndr. Obes. 7, 211-223 (2014).
68. Aguayo-Mazzucato, C. & Bonner-Weir, S. Stem cell therapy for type 1 diabetes mellitus. Nat. Rev. Endocrinol. 6, 139-148 (2010).
69. Orlando, G. et al. Cell replacement strategies aimed at reconstitution of the-cell compartment in type 1 diabetes. Diabetes 63, 1433-1444 (2014).
70. Bouwens, L., Houbracken, I. & Mfopou, J. K. The use of stem cells for pancreatic regeneration in diabetes mellitus. Nat. Rev. Endocrinol. 9, 598-606 (2013).
71. Baeyens, L. et al. In vitro generation of insulin-producing cells from adult exocrine pancreatic cells. Diabetologia 48, 49-57 (2005).
72. Collombat, P. et al. The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into and subsequently cells. Cell 138, 449-462 (2009).
73. Wu, F. et al. TNF-like weak inducer of apoptosis (TWEAK) promotes-cell neogenesis from pancreatic ductal epithelium in adult mice. PLoS ONE 8, e72132 (2013).
74. Avolio, F. et al. From pancreas morphogenesis to-cell regeneration. Curr. Top. Dev. Biol. 106, 217-238 (2013).
75. Wang, R. N., Rehfeld, J. F., Nielsen, F. C. & Klöppel, G. Expression of gastrin and transforming growth factor-during duct to islet cell differentiation in the pancreas of duct-ligated adult rats. Diabetologia 40, 887-893 (1997).
76. Boj-Carceller, D. Proton pump inhibitors: impact on glucose metabolism. Endocrine 43, 22-32 (2013).
77. Mefford, I. N. & Wade, E. U. Proton pump inhibitors as a treatment method for type II diabetes. Med. Hypotheses 73, 29-32 (2009).
78. Boj-Carceller, D. et al. Are proton pump inhibitors a new antidiabetic drug A cross sectional study. World J. Diabetes 2, 217-220 (2011).
79. Hove, K. D. et al. Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients-a retrospective analysis. Diabetes Res. Clin. Pract. 90, e72-e74 (2010).
80. Crouch, M. A., Mefford, I. N. & Wade, E. U. Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. J. Am. Board Fam. Med. 25, 50-54 (2012).
81. Guglielmi, C., Secchi, C., Maddaloni, E., Manfrini, S. & Pozzilli, P. Effects of Treatment with Proton Pump Inhibitors in Metabolic Control in Patients with type 2 Diabetes [abstract 2425PO]. Diabetes 63 (Suppl. 1), A615 (2014).
82. Singh, P. K. et al. Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 97, E2105-E2108 (2012).
83. Hove, K. D. et al. Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia 56, 22-30 (2013).
84. Pettus, J., Hirsch, I. & Edelman, S. GLP-1 agonists in type 1 diabetes. Clin. Immunol. 149, 317-323 (2013).
85. Farilla, L. et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144, 5149-5158 (2003).
86. Bunck, M. C. et al. Effects of exenatide on measures of-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34, 2041-2047 (2011).
87. Poucher, S. M. et al. Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes Obes. Metab. 14, 918-926 (2012).
88. Liang, J., Leung, K. K., Lam, S. Y. & Leung, P. S. Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells. Diabetes Obes. Metab. 14, 842-851 (2012).
89. Pospisilik, J. A. et al. Dipeptidyl peptidase IV inhibitor treatment stimulates-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52, 741-750 (2003).
90. Jelsing, J., Vrang, N., van Witteloostuijn, S. B., Mark, M. & Klein, T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves-cell mass in non-obese diabetic mice. J. Endocrinol. 214, 381-387 (2012).
91. Kim, D.-H., Lee, J.-C., Lee, M.-K., Kim, K.-W. & Lee, M.-S. Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition. Diabetologia 55, 3308-3317 (2012).
92. Cai, X., Han, X., Luo, Y. & Ji, L. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis. J. Diabetes http://dx.doi.org/10.1111/1753-0407.12196.
93. Zhao, Y., Yang, L. & Zhou, Z. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs. J. Diabetes 6, 21-29 (2014).
94. Tian, L. et al. Reversal of new-onset diabetes through modulating inflammation and stimulating-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 151, 3049-3060 (2010).
95. Zhao, Y., Yang, L., Wang, X. & Zhou, Z. The new insights of DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes. Diabetes Metab. Res. Rev. 30, 646-653 (2014).
96. Goodwin, S. R. et al. Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study. J. Clin. Endocrinol. Metab. 98, 743-751 (2013).
97. Ellis, S. L. et al. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet. Med. 28, 1176-1181 (2011).
98. Garg, S. K. et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr. Pract. 19, 19-28 (2013).
99. Zhao, Y. et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J. Clin. Endocrinol. Metab. 99, E876-E880 (2014).
100. Johansen, O. E. et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care 37, e11-e12 (2014).
101. Pozzilli, P., Buzzetti, R., Frederich, R., Iqbal, N. & Hirshberg, B. Saxagliptin increases-cell function and improves HOMA index in patients with latent autoimmune diabetes in adults [152-OR]. Diabetes 63, A41 (2014).
102. Ansarullah et al. Stimulating-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor. PLoS ONE 8, e53345 (2013).
103. Suarez-Pinzon, W. L., Cembrowski, G. S. & Rabinovitch, A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia 52, 1680-1682 (2009).
104. Suarez-Pinzon, W. L. et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57, 3281-3288 (2008).
105. Suarez-Pinzon, W. L. & Rabinovitch, A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice. Cell Transplant. 20, 1343-1349 (2011).
106. World Health Organization. Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV Infection [online], www.who.int/hiv/pub/guidelines/arv2013 (2013).
107. Maddaloni, E. & Pozzilli, P. SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes). Endocrine 46, 3-5 (2014).
108. Yacoub, T. G. Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy. Postgrad. Med. 126, 95-106 (2014).